| Year |
Citation |
Score |
| 2023 |
Lubanska D, Alrashed S, Oschanney L, Cieslukowski A, Nadi A, Habashy P, Renaud A, Roye-Azar A, Soliman M, Adili K, Baker A, Baseet M, Llancari A, Mitrevski A, Mouawad S, ... ... Porter LA, et al. E-learning and research experience exchange in the online setting of student peer mentor network during COVID-19 pandemic and beyond: A laboratory case study. Biochemistry and Molecular Biology Education : a Bimonthly Publication of the International Union of Biochemistry and Molecular Biology. PMID 37811972 DOI: 10.1002/bmb.21792 |
0.708 |
|
| 2022 |
Fidalgo da Silva E, Abu Khatir B, Drouillard C, Hinch I, Davis GO, Sameem M, Patel R, Fong J, Lubanska D, Porter LA. Tuberin levels during cellular differentiation in brain development. Differentiation; Research in Biological Diversity. 130: 43-50. PMID 36608575 DOI: 10.1016/j.diff.2022.12.004 |
0.772 |
|
| 2022 |
Lubanska D, Alrashed S, Mason GT, Nadeem F, Awada A, DiPasquale M, Sorge A, Malik A, Kojic M, Soliman MAR, deCarvalho AC, Shamisa A, Kulkarni S, Marquardt D, Porter LA, et al. Impairing proliferation of glioblastoma multiforme with CD44+ selective conjugated polymer nanoparticles. Scientific Reports. 12: 12078. PMID 35840697 DOI: 10.1038/s41598-022-15244-0 |
0.758 |
|
| 2021 |
Lubanska D, Qemo I, Byrne M, Matthews KN, Fifield BA, Brown J, da Silva EF, Porter LA. The Cyclin-Like Protein SPY1 overrides Reprogramming Induced Senescence Through EZH2 Mediated H3K27me3. Stem Cells (Dayton, Ohio). PMID 34486784 DOI: 10.1002/stem.3453 |
0.79 |
|
| 2019 |
Fifield BA, Qemo I, Kirou E, Cardiff RD, Porter LA. The atypical cyclin-like protein Spy1 overrides p53-mediated tumour suppression and promotes susceptibility to breast tumourigenesis. Breast Cancer Research : Bcr. 21: 140. PMID 31829284 DOI: 10.1186/S13058-019-1211-3 |
0.432 |
|
| 2019 |
Bakht MK, Lovnicki JM, Tubman J, Stringer KF, Chiaramonte J, Reynolds MR, Derecichei I, Ferraiuolo RM, Fifield BA, Lubanska D, Oh SW, Cheon GJ, Kwak C, Jeong CW, Kang KW, ... ... Porter LA, et al. Differential expression of glucose transporters and hexokinases in prostate cancer with a neuroendocrine gene signature: a mechanistic perspective for FDG imaging of PSMA-suppressed tumors. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31806771 DOI: 10.2967/Jnumed.119.231068 |
0.735 |
|
| 2019 |
Alkhateeb A, Rezaeian I, Singireddy S, Cavallo-Medved D, Porter LA, Rueda L. Transcriptomics Signature from Next-Generation Sequencing Data Reveals New Transcriptomic Biomarkers Related to Prostate Cancer. Cancer Informatics. 18: 1176935119835522. PMID 30890858 DOI: 10.1177/1176935119835522 |
0.309 |
|
| 2019 |
Fidalgo da Silva E, Botsford S, Dare-Shih J, Hanna MA, Porter LA. The Tuberin and Cyclin B1 complex functions as a novel G2/M sensor of serum conditions and Akt signaling. Plos One. 14: e0210612. PMID 30629673 DOI: 10.1371/Journal.Pone.0210612 |
0.432 |
|
| 2019 |
Qemo I, Porter LA. Cell Cycle Dynamics in Glioma Cancer Stem Cells. Methods in Molecular Biology (Clifton, N.J.). 1869: 117-126. PMID 30324519 DOI: 10.1007/978-1-4939-8805-1_11 |
0.537 |
|
| 2018 |
Bakht MK, Derecichei I, Li Y, Ferraiuolo RM, Dunning MJ, Oh SW, Hussein A, Youn H, Stringer KF, Jeong CW, Cheon GJ, Kwak C, Kang KW, Lamb A, Wang Y, ... ... Porter L, et al. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocrine-Related Cancer. PMID 30400059 DOI: 10.1530/Erc-18-0226 |
0.385 |
|
| 2017 |
McGrath DA, Fifield BA, Marceau AH, Tripathi S, Porter LA, Rubin SM. Structural basis of divergent cyclin-dependent kinase activation by Spy1/RINGO proteins. The Embo Journal. PMID 28666995 DOI: 10.15252/Embj.201796905 |
0.428 |
|
| 2017 |
Firoozbakht F, Rezaeian I, D'agnillo M, Porter L, Rueda L, Ngom A. An Integrative Approach for Identifying Network Biomarkers of Breast Cancer Subtypes Using Genomic, Interactomic, and Transcriptomic Data. Journal of Computational Biology : a Journal of Computational Molecular Cell Biology. PMID 28650678 DOI: 10.1089/Cmb.2017.0010 |
0.315 |
|
| 2017 |
Ferraiuolo RM, Tubman J, Sinha I, Hamm C, Porter LA. The cyclin-like protein, SPY1, regulates the ERα and ERK1/2 pathways promoting tamoxifen resistance. Oncotarget. 8: 23337-23352. PMID 28423577 DOI: 10.18632/Oncotarget.15578 |
0.368 |
|
| 2017 |
Lubanska D, Porter L. Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme. Drugs in R&D. PMID 28324583 DOI: 10.1007/S40268-017-0180-1 |
0.776 |
|
| 2017 |
Bakht MK, Oh SW, Hwang DW, Lee YS, Youn H, Porter LA, Cheon GJ, Kwak C, Lee DS, Kang KW. The potential roles of radionanomedicine and radioexosomic in prostate cancer research and treatment. Current Pharmaceutical Design. PMID 28215159 DOI: 10.2174/1381612823666170216122412 |
0.31 |
|
| 2017 |
Bazzi ZA, Balun J, Cavallo-Medved D, Porter LA, Boffa MB. Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells: potential relevance to the breast tumour microenvironment. Clinical & Experimental Metastasis. PMID 28124276 DOI: 10.1007/S10585-017-9837-Y |
0.404 |
|
| 2016 |
Bazzi ZA, Lanoue D, El-Youssef M, Romagnuolo R, Tubman J, Cavallo-Medved D, Porter LA, Boffa MB. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis. Bmc Cancer. 16: 328. PMID 27221823 DOI: 10.1186/S12885-016-2359-1 |
0.383 |
|
| 2016 |
Rezaeian I, Tavakoli A, Cavallo-Medved D, Porter LA, Rueda L. A Novel Model Used to Detect Differential Splice Junctions as Biomarkers in Prostate Cancer from RNA-Seq Data. Journal of Biomedical Informatics. PMID 26992567 DOI: 10.1016/J.Jbi.2016.03.010 |
0.341 |
|
| 2016 |
Al Sorkhy M, Fifield BA, Myers D, Porter LA. Direct interactions with both p27 and Cdk2 regulate Spy1-mediated proliferation in vivo and in vitro. Cell Cycle (Georgetown, Tex.). 15: 128-136. PMID 26771716 DOI: 10.1080/15384101.2015.1121327 |
0.367 |
|
| 2016 |
Fidalgo da Silva E, Botsford S, Porter LA. Derivation of a novel G2 reporter system. Cytotechnology. 68: 19-24. PMID 24981314 DOI: 10.1007/S10616-014-9757-5 |
0.368 |
|
| 2015 |
Crozier M, Porter LA. Paclitaxel-induced transcriptional regulation of Fas signaling pathway is antagonized by dexamethasone. Breast Cancer Research and Treatment. 154: 33-44. PMID 26463651 DOI: 10.1007/S10549-015-3588-8 |
0.389 |
|
| 2015 |
Bazzi ZA, Rudy D, Porter LA, Cavallo-Medved D, Boffa MB. Abstract P1-07-32: Activated thrombin activatable fibrinolysis inhibitor is a novel anti-metastatic factor in breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P1-07-32 |
0.429 |
|
| 2014 |
Lubanska D, Porter LA. The atypical cell cycle regulator Spy1 suppresses differentiation of the neuroblastoma stem cell population. Oncoscience. 1: 336-48. PMID 25594028 |
0.807 |
|
| 2014 |
Lubanska D, Porter LA. Atypical cell cycle control over neural cell fate. Cell Cycle (Georgetown, Tex.). 13: 2987. PMID 25486555 DOI: 10.4161/15384101.2014.962849 |
0.804 |
|
| 2014 |
Lubanska D, Market-Velker BA, deCarvalho AC, Mikkelsen T, Fidalgo da Silva E, Porter LA. The cyclin-like protein Spy1 regulates growth and division characteristics of the CD133+ population in human glioma. Cancer Cell. 25: 64-76. PMID 24434210 DOI: 10.1016/J.Ccr.2013.12.006 |
0.784 |
|
| 2014 |
Lubanska D, Porter LA. The atypical cell cycle regulator Spy1 suppresses differentiation of the neuroblastoma stem cell population Oncoscience. 1: 336-348. DOI: 10.18632/oncoscience.36 |
0.807 |
|
| 2012 |
Al Sorkhy M, Ferraiuolo RM, Jalili E, Malysa A, Fratiloiu AR, Sloane BF, Porter LA. The cyclin-like protein Spy1/RINGO promotes mammary transformation and is elevated in human breast cancer. Bmc Cancer. 12: 45. PMID 22280365 DOI: 10.1186/1471-2407-12-45 |
0.751 |
|
| 2011 |
Fidalgo da Silva E, Ansari SB, Maimaiti J, Barnes EA, Kong-Beltran M, Donoghue DJ, Porter LA. The tumor suppressor tuberin regulates mitotic onset through the cellular localization of cyclin B1. Cell Cycle (Georgetown, Tex.). 10: 3129-39. PMID 21900748 DOI: 10.4161/Cc.10.18.17296 |
0.331 |
|
| 2009 |
Al Sorkhy M, Craig R, Market B, Ard R, Porter LA. The cyclin-dependent kinase activator, Spy1A, is targeted for degradation by the ubiquitin ligase NEDD4. The Journal of Biological Chemistry. 284: 2617-27. PMID 19054764 DOI: 10.1074/Jbc.M804847200 |
0.447 |
|
| 2008 |
Golipour A, Myers D, Seagroves T, Murphy D, Evan GI, Donoghue DJ, Moorehead RA, Porter LA. The Spy1/RINGO family represents a novel mechanism regulating mammary growth and tumorigenesis. Cancer Research. 68: 3591-600. PMID 18483240 DOI: 10.1158/0008-5472.Can-07-6453 |
0.406 |
|
| 2007 |
McAndrew CW, Gastwirt RF, Meyer AN, Porter LA, Donoghue DJ. Spy1 enhances phosphorylation and degradation of the cell cycle inhibitor p27. Cell Cycle (Georgetown, Tex.). 6: 1937-45. PMID 17671428 DOI: 10.4161/Cc.6.15.4520 |
0.362 |
|
| 2003 |
Porter LA, Kong-Beltran M, Donoghue DJ. Spy1 interacts with p27Kip1 to allow G1/S progression. Molecular Biology of the Cell. 14: 3664-74. PMID 12972555 DOI: 10.1091/Mbc.E02-12-0820 |
0.444 |
|
| 2002 |
Porter LA, Dellinger RW, Tynan JA, Barnes EA, Kong M, Lenormand JL, Donoghue DJ. Human Speedy: a novel cell cycle regulator that enhances proliferation through activation of Cdk2. The Journal of Cell Biology. 157: 357-66. PMID 11980914 DOI: 10.1083/Jcb.200109045 |
0.487 |
|
| Show low-probability matches. |